美国 · 平台与数据 · Finviz

Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans

来源：Finviz · 美国 3 天前

Fractyl Health reports statistically significant reductions in weight regain following GLP-1 discontinuation, advancing its Revita treatment toward a potential FDA submission in…

在 Finviz 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (finviz.com)

Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans

推荐阅读

Franco-Nevada Co. (FNV.TO) - What Are Researchers Thinking About This Stock?

RLI Non-GAAP EPS of $0.86 beats by $0.33, revenue of $476.9M beats by $9.8M

Colleges raced to build massive computer-science departments. Now the boom is turning to bust.

First Solar leads green energy stocks on value and free cash flow

Anthropic is AI trade's last big hope for a major IPO this year

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans

分享

推荐阅读

Franco-Nevada Co. (FNV.TO) - What Are Researchers Thinking About This Stock?

RLI Non-GAAP EPS of $0.86 beats by $0.33, revenue of $476.9M beats by $9.8M

Colleges raced to build massive computer-science departments. Now the boom is turning to bust.

First Solar leads green energy stocks on value and free cash flow

Anthropic is AI trade's last big hope for a major IPO this year

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030